Mesothelioma research can be expected to make great strides in the coming years thanks to new exciting work underway now all over the world by young scientific investigators. Five of this promising group just received the Young Investigator Travel Awards at the twelfth biennial meeting of the International Mesothelioma Interest Group (iMig 2014), held in Capetown, South Africa. Our firm is proud to have initiated this important award in 2008 and to continue to sponsor it. On behalf of all of us at Kazan, McClain, Satterley and Greenwood, we would like to offer our congratulations on receiving the Young Investigator Travel Awards to each of these promising young mesothelioma research scientists.
Their achievements are a source of pride and inspiration to all of us involved in mesothelioma who seek new pathways to treat and cure this devastating disease. We hope they realize how many people – those with mesothelioma, their families and those of us who strive to help them medically and legally – appreciate the outstanding work they are doing in this field.
It is always a pleasure to see hard-working forward-thinking young researchers receiving the recognition they deserve. The award reflects the endless hours they have spent in their labs on their mesothelioma research projects.
We look forward to seeing the results of their future work in mesothelioma research and wish them every success.
2014 iMig Young Investigator Award Recipients
Sébastien Anguille, MD is a researcher at the University of Antwerp and Antwerp University Hospital Edegem Belgium. He is one of the authors of a recent paper “Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study” published in the Journal of Clinical Oncology.
Lincun Wu, MD is a research associate with the University Health Network in Toronto, Canada’s Mesothelioma Research Program at the Princess Margaret Cancer Center. There, Dr. Wu is involved in a research project to improve the outcome of mesothelioma by combining chemotherapy with immunotherapy.
Alistair Cook, PhD is a research assistant professor in the School of Medicine and Pharmacology of the University of Western Australia. He is the lead author of a recent study about a potential new way to improve anti-tumor immunity or chemo-immunotherapy efficacy in mesothelioma treatment.
Tanguy Siewert, MD is an assistant professor of medicine at the University of Chicago. He specializes in head, neck and lung cancers. He studies which novel drugs appear most promising, which individual tumors are more likely to respond to these treatments, and how to successfully combine therapies. Dr. Seiwert uses this pre-clinical knowledge to develop new treatments for use in clinical trials, and to ultimately improve patient care.
Kimberly Birnie is earning a PhD at the Lung Institute of the University of Western Australia where she is focused on malignant mesothelioma research. She has been recognized by the Thoracic Society of Australia and New Zealand for her work